Huijskens Elisabeth, Rossen John, Mulder Paul, van Beek Ruud, van Vugt Hennie, Verbakel Johannes, Rimmelzwaan Guus, Koopmans Marion, Peeters Marcel
Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, P.O. 747, 5000 AS Tilburg, Netherlands.
Clin Vaccine Immunol. 2011 Sep;18(9):1401-5. doi: 10.1128/CVI.05046-11. Epub 2011 Jul 27.
The emergence of a new influenza A virus (H1N1) variant in 2009 led to a worldwide vaccination program, which was prepared in a relatively short period of time. This study investigated the humoral immunity against this virus before and after vaccination with a 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine, as well as the persistence of vaccine-induced antibodies. Our prospective longitudinal study included 498 health care workers (mean age, 43 years; median age, 44 years). Most (89%) had never or only occasionally received a seasonal influenza virus vaccine, and 11% were vaccinated annually (on average, for >10 years). Antibody titers were determined by a hemagglutination inhibition (HI) assay at baseline, 3 weeks after the first vaccination, and 5 weeks and 7 months after the second vaccination. Four hundred thirty-five persons received two doses of the 2009 vaccine. After the first dose, 79.5% developed a HI titer of ≥40. This percentage increased to 83.3% after the second dose. Persistent antibodies were found in 71.9% of the group that had not received annual vaccinations and in 43.8% of the group that had received annual vaccinations. The latter group tended to have lower HI titers (P=0.09). With increasing age, HI titers decreased significantly, by 2.4% per year. A single dose of the 2009 vaccine was immunogenic in almost 80% of the study population, whereas an additional dose resulted in significantly increased titers only in persons over 50. Finally, a reduced HI antibody response against the 2009 vaccine was found in adults who had previously received seasonal influenza virus vaccination. More studies on the effect of yearly seasonal influenza virus vaccination on the immune response are warranted.
2009年一种新型甲型流感病毒（H1N1）变体的出现引发了一项全球疫苗接种计划，该计划在相对较短的时间内就准备就绪。本研究调查了接种2009年甲型流感病毒（H1N1）单价MF59佐剂疫苗前后针对该病毒的体液免疫情况，以及疫苗诱导抗体的持久性。我们的前瞻性纵向研究纳入了498名医护人员（平均年龄43岁；年龄中位数44岁）。大多数人（89%）从未或仅偶尔接种过季节性流感病毒疫苗，11%的人每年接种（平均超过10年）。在基线、首次接种后3周、第二次接种后5周和7个月时，通过血凝抑制（HI）试验测定抗体滴度。435人接种了两剂2009年疫苗。接种第一剂后，79.5%的人HI滴度≥40。接种第二剂后，这一比例增至83.3%。在未每年接种疫苗的人群中，71.9%发现有持续抗体，在每年接种疫苗的人群中这一比例为43.8%。后一组的HI滴度往往较低（P = 0.09）。随着年龄增长，HI滴度显著下降，每年下降2.4%。单剂2009年疫苗在近80%的研究人群中具有免疫原性，而额外一剂仅在50岁以上人群中导致滴度显著升高。最后，发现先前接种过季节性流感病毒疫苗的成年人对2009年疫苗的HI抗体反应降低。有必要开展更多关于每年接种季节性流感病毒疫苗对免疫反应影响的研究。
